These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7624666)

  • 1. [Cancer following treatment of Hodgkin disease].
    Lustman F; Nouwynck C
    Rev Med Brux; 1995; 16(3):138-40. PubMed ID: 7624666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low grade non-Hodgkin's lymphoma after combined therapy for Hodgkin's disease].
    Raya Sánchez JM; González Brito G; Hernández Nieto L; Brito Barroso ML; Alvarez Argüelles H; Jorge Hernández JA; Martín Herrera A
    Sangre (Barc); 1994 Dec; 39(6):461-4. PubMed ID: 7855699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
    Glanzmann C; Veraguth A; Lütolf UM
    Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-Hodgkin's lymphoma in a patient after many years of remission of Hodgkin's disease].
    Kaźmierczak M; Komarnicki M; Kroll R
    Acta Haematol Pol; 1995; 26(3):311-3. PubMed ID: 8525778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The probability of the carcinogenic risk of using nitrosomethylurea for treating cancer patients].
    Korman DB
    Vopr Onkol; 2000; 46(3):274-7. PubMed ID: 10976271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
    Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late complications of Hodgkin's disease management.
    Young RC; Bookman MA; Longo DL
    J Natl Cancer Inst Monogr; 1990; (10):55-60. PubMed ID: 2189477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease.
    Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K
    Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukemia after the treatment of Hodgkin's disease.
    Henry-Amar M; Dietrich PY
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):369-87. PubMed ID: 8468271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.
    Sont JK; van Stiphout WA; Noordijk EM; Molenaar J; Zwetsloot-Schonk JH; Willemze R; Vandenbroucke JP
    Ann Hematol; 1992 Nov; 65(5):213-8. PubMed ID: 1457578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid second cancers following Hodgkin's disease.
    Tucker MA
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):389-400. PubMed ID: 8468272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Late treatment related complications of Hodgkin's disease].
    Henry-Amar M; Gisselbrecht C
    Rev Prat; 1998 May; 48(10):1092-7. PubMed ID: 9781154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.